search

US accuses Israel’s Teva of fixing drug prices

Justice Department says between 2013 and 2015 Teva and several co-conspirators agreed to ‘fix prices, rig bids, and allocate customers for generic drugs

A man walks out of Teva Pharmaceutical facility building in Neot Hovav, Israel, Thursday, Dec. 14, 2017. (AP Photo/Tsafrir Abayov)
A man walks out of Teva Pharmaceutical facility building in Neot Hovav, Israel, Thursday, Dec. 14, 2017. (AP Photo/Tsafrir Abayov)

NEW YORK — The US Justice Department on Tuesday charged Israeli generic drug giant Teva of illegally fixing drug prices between 2013 and 2015.

Teva and several co-conspirators agreed to “fix prices, rig bids, and allocate customers for generic drugs” including the popular cholesterol-regulating medicine Pravastatin, the Justice Department said in a statement.

Patients would have paid a total of $350 million more than they should have, the department said.

Five companies investigated in the case have already paid heavy fines to avoid prosecution.

Sandoz, a subsidiary of the Swiss pharmaceutical giant Novartis, agreed to pay $195 million in March, and the American subsidiary of the Israeli group Taro Pharmaceuticals agreed to pay $205.7 million in July.

Other companies involved include Apotex, which agreed to pay a $24.1 million fine in May, and Glenmark, which was indicted by a grand jury in July.

Teva, which sold $17 billion worth of drugs last year, was also accused earlier this month by US authorities of artificially inflating the reimbursement price for its multiple sclerosis drug Copaxone for patients in the government-run Medicare program.

read more:
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.